Online inquiry

IVTScrip™ mRNA-Anti-CD3E&MS4A1, REGN-1979(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ13864MR)

This product GTTS-WQ13864MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets CD3E&MS4A1 gene. The antibody can be applied in Chronic lymphocytic leukemia (CLL), Non-Hodgkin's lymphoma (NHL) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_000733.4; NM_021950.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 916; 931
UniProt ID P07766; P11836
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD3E&MS4A1, REGN-1979(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ13864MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ3456MR IVTScrip™ mRNA-Anti-S, AZD8895(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA AZD8895
GTTS-WQ7302MR IVTScrip™ mRNA-Anti-CSF1R, FPA-008(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA FPA-008
GTTS-WQ15325MR IVTScrip™ mRNA-Anti-TNF, TNFRSF1B-Fc(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA TNFRSF1B-Fc
GTTS-WQ13224MR IVTScrip™ mRNA-Anti-TNFRSF9, PF-05082566(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA PF-05082566
GTTS-WQ4440MR IVTScrip™ mRNA-Anti-CTLA4, BMS-734016(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA BMS-734016
GTTS-WQ11434MR IVTScrip™ mRNA-Anti-F, MEDI-8897(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA MEDI-8897
GTTS-WQ5910MR IVTScrip™ mRNA-Anti-IL31RA, CIM 331(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA CIM 331
GTTS-WQ7568MR IVTScrip™ mRNA-Anti-GPC3, GC33(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA GC33
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW